Ensysce Biosciences(ENSC)
$0.42+0.03 (+8.01%)
ENSC
Ensysce Biosciences financials statements
$0.42
At close:+0.03 (+8.01%)
Want to see ENSC full AI Analyst Report?
Ensysce Biosciences (ENSC) Ratios
323 Followers
Ensysce Biosciences Ratios
ENSC's free cash flow for Q3 2026 was $-1.45M. For the 2026 fiscal year, ENSC's free cash flow was decreased by $-51.75K and operating cash flow was $-1.40M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.59 | 2.42 | 0.69 | 0.56 | 0.95 |
| Quick Ratio | 1.59 | 2.42 | 0.69 | 0.56 | 0.98 |
| Cash Ratio | 0.94 | 1.59 | 0.34 | 0.33 | 0.74 |
| Solvency Ratio | -2.23 | -3.60 | -3.16 | -2.44 | -1.18 |
| Operating Cash Flow Ratio | -1.71 | -3399198.17 | -3.23 | -1.89 | -0.50 |
| Short-Term Operating Cash Flow Coverage | -25.45 | -24871378.37 | -12.61 | -4.19 | -0.65 |
| Net Current Asset Value | $ 2.67M | $ 3.13M | $ -1.07M | $ -4.62M | $ -8.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.05 | 0.32 | 0.75 | 1.05 |
| Debt-to-Equity Ratio | 0.10 | 0.08 | -2.65 | -1.19 | -2.19 |
| Debt-to-Capital Ratio | 0.09 | 0.08 | 1.61 | 6.16 | 1.84 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -0.04 | -1.29 |
| Financial Leverage Ratio | 2.32 | 1.51 | -8.39 | -1.58 | -2.08 |
| Debt Service Coverage Ratio | -31.19 | -4.23 | -8.87 | -5.54 | -1.85 |
| Interest Coverage Ratio | -545.69 | -5.22 | -30.28 | -221.16 | -15.34 |
| Debt to Market Cap | 0.13 | 0.02 | 0.02 | 0.18 | 0.01 |
| Interest Debt Per Share | 0.13 | 0.91 | 0.53 | 25.25 | 220.30 |
| Net Debt to EBITDA | 0.39 | 0.48 | 0.03 | -0.05 | -0.19 |
| Profitability Margins | |||||
| Gross Profit Margin | -104.81% | -38.57% | -240.12% | -686.08% | 100.00% |
| EBIT Margin | -200.48% | -129.17% | -480.41% | -959.91% | -734.32% |
| EBITDA Margin | -200.35% | -129.17% | -480.41% | -959.90% | -734.32% |
| Operating Profit Margin | -202.12% | -129.17% | -480.41% | -959.91% | -562.71% |
| Pretax Profit Margin | -200.85% | -153.30% | -476.29% | -959.33% | -825.38% |
| Net Profit Margin | -200.84% | -153.30% | -475.71% | -957.93% | -823.62% |
| Continuous Operations Profit Margin | -200.85% | -153.30% | -476.29% | -959.33% | -825.38% |
| Net Income Per EBT | 100.00% | 100.00% | 99.88% | 99.85% | 99.79% |
| EBT Per EBIT | 99.37% | 118.68% | 99.14% | 99.94% | 146.68% |
| Return on Assets (ROA) | -136.54% | -142.70% | -391.90% | -410.74% | -177.15% |
| Return on Equity (ROE) | -316.63% | -215.37% | 3287.20% | 650.76% | 369.16% |
| Return on Capital Employed (ROCE) | -355.00% | -198.52% | 1715.21% | 676.75% | 30894.52% |
| Return on Invested Capital (ROIC) | -320.89% | -182.30% | -4663.69% | -3388.81% | -156.35% |
| Return on Tangible Assets | -136.54% | -142.70% | -391.90% | -410.74% | -177.15% |
| Earnings Yield | -432.56% | -56.17% | -29.48% | -99.51% | -2.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.05 | 41.98 | 22.87 | 9.12 | 7.99 |
| Payables Turnover | 3.18 | 5.32 | 3.92 | 6.74 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Fixed Asset Turnover | 40.82 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.68 | 0.93 | 0.82 | 0.43 | 0.22 |
| Working Capital Turnover Ratio | 1.74 | 4.98 | -0.86 | -1.01 | -0.94 |
| Cash Conversion Cycle | -84.65 | -59.92 | -77.18 | -14.13 | -1795524.71 |
| Days of Sales Outstanding | 30.28 | 8.70 | 15.96 | 40.04 | 45.66 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | -1067736.19 |
| Days of Payables Outstanding | 114.94 | 68.62 | 93.14 | 54.17 | 727834.17 |
| Operating Cycle | 30.28 | 8.70 | 15.96 | 40.04 | -1067690.53 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.05 | -4294619.35 | -4.76 | -99.41 | -98.10 |
| Free Cash Flow Per Share | -3.10 | -4294619.35 | -4.76 | -99.41 | -98.10 |
| Dividend Paid and CapEx Coverage Ratio | -63.14 | -25871.38 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -63.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -25.45 | -24871378.37 | -12.61 | -4.03 | -0.48 |
| Operating Cash Flow to Sales Ratio | -1.54 | -1440057.58 | -4.83 | -7.09 | -2.33 |
| Free Cash Flow Yield | -337.09% | -52759451.44% | -29.95% | -73.64% | -0.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.23 | -1.78 | -3.39 | -1.00 | -48.88 |
| Price-to-Sales (P/S) Ratio | 0.46 | 2.73 | 16.14 | 9.63 | 402.58 |
| Price-to-Book (P/B) Ratio | 0.73 | 3.83 | -111.50 | -6.54 | -180.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.30 | -0.00 | -3.34 | -1.36 | -172.48 |
| Price-to-Operating Cash Flow Ratio | -0.30 | -0.00 | -3.34 | -1.36 | -172.48 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.70 | 0.04 | 0.02 | 0.00 |
| Enterprise Value Multiple | 0.16 | -1.64 | -3.33 | -1.06 | -55.01 |
| Enterprise Value | -1.65M | 11.02M | 35.73M | 25.58M | 1.43B |
| EV to EBITDA | 0.16 | -1.64 | -3.33 | -1.06 | -55.01 |
| EV to Sales | -0.33 | 2.12 | 16.01 | 10.14 | 403.98 |
| EV to Free Cash Flow | 0.21 | -0.00 | -3.31 | -1.43 | -173.08 |
| EV to Operating Cash Flow | 0.21 | -0.00 | -3.31 | -1.43 | -173.08 |
| Tangible Book Value Per Share | 1.13 | 1.93 | -0.29 | -22.40 | -97.10 |
| Shareholders’ Equity Per Share | 1.26 | 2.12 | -0.14 | -20.64 | -93.77 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.98 | 2.98 | 0.99 | 14.02 | 42.03 |
| Net Income Per Share | -3.98 | -4.57 | -4.69 | -134.34 | -346.16 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.19 | 0.99 | 1.00 | 1.12 |
| Research & Development to Revenue | 2.05 | 1.39 | 3.40 | 7.86 | 1.33 |
| SG&A to Revenue | 0.97 | 0.91 | 2.40 | 2.74 | 0.00 |
| Stock-Based Compensation to Revenue | 0.03 | 21252.02 | 0.39 | 0.42 | 0.03 |
| Income Quality | 0.77 | 939362.91 | 1.01 | 0.74 | 0.28 |
Currency in USD

